Beta Bionics, Inc. (BBNX)
NASDAQ: BBNX · Real-Time Price · USD
29.89
+5.61 (23.11%)
Oct 29, 2025, 10:58 AM EDT - Market open

Beta Bionics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22
88.5765.12120.18
Revenue Growth (YoY)
67.01%442.93%6601.12%-
Cost of Revenue
40.2929.245.69-
Gross Profit
48.2835.896.310.18
Selling, General & Admin
8354.9624.2233.5
Research & Development
33.8726.1817.9431.43
Operating Expenses
116.8881.1442.1664.92
Operating Income
-68.59-45.25-35.85-64.74
Interest Expense
----0.01
Interest & Investment Income
9.233.911.780.2
Other Non Operating Income (Expenses)
-18.47-13.41-10.030.91
EBT Excluding Unusual Items
-77.84-54.76-44.1-63.65
Other Unusual Items
----1.1
Pretax Income
-77.84-54.76-44.1-64.75
Net Income
-77.84-54.76-44.1-64.75
Net Income to Common
-77.84-54.76-44.1-64.75
Shares Outstanding (Basic)
31655
Shares Outstanding (Diluted)
31655
Shares Change (YoY)
401.79%20.01%6.13%-
EPS (Basic)
-2.50-8.60-8.31-12.96
EPS (Diluted)
-2.50-8.60-8.31-12.96
Free Cash Flow
-60.53-51.67-32.85-60.98
Free Cash Flow Per Share
-1.94-8.12-6.19-12.20
Gross Margin
54.51%55.11%52.59%100.00%
Operating Margin
-77.45%-69.48%-298.88%-36169.83%
Profit Margin
-87.89%-84.08%-367.64%-36173.74%
Free Cash Flow Margin
-68.34%-79.34%-273.84%-34067.04%
EBITDA
-67.33-44.1-34.62-63.4
EBITDA Margin
-76.02%-67.72%-288.65%-
D&A For EBITDA
1.271.151.231.35
EBIT
-68.59-45.25-35.85-64.74
EBIT Margin
-77.45%-69.48%-298.87%-
Revenue as Reported
---0.18
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q